3D bioprinting for cancer modeling and drug screening
Aurélie Cadiou, Eva-Laure Peiller Matera, Nicolas Ellinger, Lars Petter Jordheim, Michael Duruisseaux, Christophe Marquette, Charles Dumontet · 2026
Read 3D bioprinting for cancer modeling and drug screening by Aurélie Cadiou, Eva-Laure Peiller Matera, Nicolas Ellinger, Lars Petter Jordheim, Michael Duruisseaux, Christophe Marquette, Charles Dumontet (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13536750.txt.
Description
Aurélie Cadiou and co-authors review three-dimensional bioprinting for cancer modeling and drug testing in a 2026 survey of the field. Printing places several cell types into shaped structures that mimic tumors more closely than flat cell layers. Models can also allow immune cells to move inside. The review weighs gains in realism against technical limits that still block wide preclinical use.
Printed models better match real tumors in cell shape, cell contact, drug spread, and drug response than flat cultures do. Printing works across many tumor lines at modest cost and can run from days to weeks, including with samples taken directly from patients. Hurdles remain around vessel growth, consistency, and scale. The authors argue that solving those hurdles would make printed tumors a stronger screen before human trials.
Catalog record
| CREATOR | Aurélie Cadiou, Eva-Laure Peiller Matera, Nicolas Ellinger, Lars Petter Jordheim, Michael Duruisseaux, Christophe Marquette, Charles Dumontet |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 82569 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |